Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E23.83 EPS (ttm)7.41 Insider Own0.10% Shs Outstand760.32M Perf Week11.35%
Market Cap134.26B Forward P/E16.68 EPS next Y10.59 Insider Trans-9.99% Shs Float759.10M Perf Month13.94%
Income5.71B PEG2.11 EPS next Q2.34 Inst Own82.60% Short Float1.20% Perf Quarter10.66%
Sales20.58B P/S6.53 EPS this Y0.90% Inst Trans0.28% Short Ratio2.83 Perf Half Y17.17%
Book/sh34.83 P/B5.07 EPS next Y10.04% ROA8.20% Target Price183.25 Perf Year41.25%
Cash/sh35.67 P/C4.95 EPS next 5Y11.28% ROE22.40% 52W Range122.43 - 174.80 Perf YTD12.00%
Dividend3.16 P/FCF23.14 EPS past 5Y8.20% ROI10.20% 52W High1.02% Beta0.56
Dividend %1.79% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin80.70% 52W Low44.23% ATR4.54
Employees17900 Current Ratio5.50 Sales Q/Q11.30% Oper. Margin37.00% RSI (14)71.80 Volatility3.60% 2.39%
OptionableYes Debt/Eq1.14 EPS Q/Q50.70% Profit Margin27.70% Rel Volume2.26 Prev Close171.69
ShortableYes LT Debt/Eq1.13 EarningsJul 30 AMC Payout34.90% Avg Volume3.21M Price176.59
Recom2.50 SMA209.71% SMA5010.92% SMA20011.70% Volume7,233,937 Change2.85%
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Jul-31-15 10:29PM  Amgen to Undergo Experimental Treatment at The Wall Street Journal
06:21PM  Stock Market Today - 07/31/15
05:00PM  Stocks Give Back Earlier Gains Friday
04:45PM  Amgen raises profit outlook after posting a strong second quarter at
03:35PM  Amgen Stock Hits High As Street Eyes Growth Drivers at Investor's Business Daily
03:31PM  Amgen (AMGN) Stock Higher as Barclays Increases Price Target at TheStreet
02:41PM  Amgen Crushes Wall Street's Expectations in Q2, But This Figure Is a Bit Worrisome at Motley Fool
02:40PM  Energy ETFs Whacked By Chevron, Exxon Mobil at Investor's Business Daily
01:43PM  Amgen to Undergo Experimental Treatment at The Wall Street Journal
12:00PM  Stocks Trade Modestly Higher Early Friday
11:02AM  This is Why Amgen is Soaring at
09:42AM  Amgen (AMGN) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
09:21AM  Amgen Beats on Q2 Earnings & Revenues, Raises Outlook - Analyst Blog
09:19AM  Stocks Futures Reverse Higher; Skywest, LinkedIn, Expedia In Motion at Investor's Business Daily
09:01AM  Exxon Mobil profit drop; LinkedIn growth; Royal Caribbean sails higher
09:01AM  Morning Movers: Amgen Jumps on Earnings; Exxon, Chevron Tumble at
08:38AM  Early movers: TYC, EA, NWL, LM, ITT, WY & more at CNBC
08:17AM  Wall Street's roller coaster; Oil companies struggle; Game of Thrones bonus
03:49AM  Edited Transcript of AMGN earnings conference call or presentation 30-Jul-15 9:00pm GMT
Jul-30-15 06:51PM  Amgen hikes 2015 forecast after 2Q increase in profit, sales
06:49PM  Amgen, Alexion Top Views, But Their Outlooks Differ
06:02PM  Key Takeaways from Amgen's (AMGN) Q2 Earnings Report - Stocks in the News
05:58PM  Fast Money Final Trade: LNKD, FEYE, EA & AMGN
05:50PM  Amgen's profit jumps 7% in 2nd quarter as sales rise, costs decline at Los Angeles Times
05:44PM  Amgen Raises 2015 Outlook, Results Beat Expectations at The Wall Street Journal
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:40PM  Amgen tops Street 2Q forecasts
04:38PM  Amgen (AMGN) Stock Gains in After-Hours Trading on Earnings Beat at TheStreet
04:30PM  Kezar scores with new way to tackle autoimmune diseases at
04:26PM  Amgen Earnings Point to New 52-Week High
04:21PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Officer
04:16PM  Amgen shares rise after quarterly results top Street view at MarketWatch
04:07PM  Amgen profit tops Street view, boosts full-year forecast
04:05PM  Amgen Announces Appointment Of Fred Hassan To Board Of Directors PR Newswire
04:04PM  Amgen Tops Analysts Profit Estimates, Raises 2015 Forecast at Bloomberg
04:01PM  Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 PR Newswire
02:53PM  Stocks Stay Mixed; Cavium Reverses Higher at Investor's Business Daily
02:52PM  Even With Recent Declines, Investors Still Love Biotech ETFs
01:33PM  Trades to go as FireEye, Amgen get ready to report at CNBC
12:58PM  Top trades for the 2nd half
11:23AM  What to Expect from Amgen Earnings
09:30AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
08:00AM  This biotech stock is about to break out: Trader at CNBC
07:07AM  Q2 2015 Amgen Inc Earnings Release - After Market Close
Jul-29-15 03:11PM  5 stocks to watch at MarketWatch
11:48AM  Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
11:02AM  Four Reasons Gilead Can Head Higher at
09:04AM  Eli Lilly & Co. Earnings Analysis: By the Numbers
09:03AM  Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
Jul-28-15 05:46PM  Amgen Announces 2015 Third Quarter Dividend PR Newswire
05:12PM  Gilead higher after earnings beat
04:25PM  Will Amgen (AMGN) Keep the Earnings Streak Alive in 2Q? - Analyst Blog
02:30PM  Amgen Stock Clears Buy Point Ahead Of Earnings
01:18PM  Is More M&A On The Way For Large-Cap Biotechs?
12:08PM  NantKwest Surges As Biggest Biotech Market Cap IPO at Investor's Business Daily
10:35AM  Biogens 2Q15 Earnings Beat Wall Street Estimates
10:02AM  Wait, Will Allergan Really Buy Biogen or Amgen? at
12:14AM  Patients Seeking Alternatives to Statins May Undergo Rigorous Vetting at The Wall Street Journal
Jul-27-15 06:26PM  3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release at Motley Fool
05:23PM  Next biotech deal brewing?
04:01PM  Amgen Announces Webcast of 2015 Second Quarter Financial Results PR Newswire
03:14PM  Allergan to own 10% stake in Teva
02:56PM  Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval at Motley Fool
02:39PM  4 Stocks Spiking on Unusual Volume at TheStreet
02:37PM  The Most Incredible Biotech Success Ever Faces Its Moment of Truth
12:43PM  Why Regeneron's Approval is Bad News For Esperion Therapeutics at
11:45AM  Biogen: Buy the Stock Get the Pipeline for Free at
05:46AM  Teva to buy Allergan generic drug business for $40.5 bln
04:25AM  Biotech high flyers face gravity test at Financial Times
Jul-26-15 11:45PM  This Weeks Earnings Calendar
10:21AM  BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead at 24/7 Wall St.
Jul-24-15 06:31PM  FDA OKs breakthrough cholesterol drug for high-risk patients
05:24PM  Regeneron Cholesterol Fighter Wins FDA OK, With Conditions
03:35PM  Earnings Growth Hard to Come By - Earnings Preview
03:20PM  Near the end, Onyx delivers once more with cancer-fighting drug at
03:04PM  FDA Approves Amgen's Kyprolis for Earlier Myeloma Treatment at The Wall Street Journal
02:23PM  FDA approves Sanofi/Regeneron cholesterol drug with limits Reuters
02:09PM  Biogen: Run Lola Run? at
12:50PM  Week in Review, July 25 at Financial Times
12:40PM  FDA Approves Kyprolis┬« (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma PR Newswire
08:38AM  AbbVie beats 2Q profit forecasts, but sales fall short
07:07AM  Sanofi's big new cholesterol drug wins European green light Reuters
Jul-23-15 05:30PM  Cholesterol drug wars
11:52AM  Celgene Hikes Outlook: But What About the Receptos Dilution? at
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
09:00AM  Amgen Submits Supplemental New Drug Application For Kyprolis┬« (Carfilzomib) In Relapsed Multiple Myeloma PR Newswire
Jul-22-15 04:25PM  Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog
02:00PM  Don't underestimate earnings power in biotech: Pro
01:41PM  Court of Appeals Biosimilars Decision Does Not Assure Zarxio Launch in September
01:17PM  Amgen Inc. Grabs a Potential Blockbuster Approval at Motley Fool
10:52AM  Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
06:38AM  Novartis, Tory Burch, Ashley Madison: Intellectual Property at Bloomberg
06:00AM  These Superhumans Are Real and Their DNA Could Be Worth Billions at Bloomberg
06:00AM  These Superhumans Are Real and Their DNA Could Be Worth Billions
03:37AM  Amgen and Sanofi to battle for cholesterol-busting crown at Financial Times
12:13AM  Novartis Can Sell Copycat of Amgens Neupogen in September, Court Rules at The Wall Street Journal
Jul-21-15 10:06PM  Europe approves Amgen's new cholesterol-lowering drug Repatha at Los Angeles Times
08:14PM  Appeals court says rival can sell copy of Amgen drug Neupogen at Los Angeles Times
06:35PM  Novartis Wins Court Battle to Sell a Biosimilar Version of an Amgen Drug at The Wall Street Journal
03:54PM  Court ruling clears way for Novartis' low-cost biotech drug
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM